Literature DB >> 15826835

Understanding mesenchymal cancer: the liposarcoma-associated FUS-DDIT3 fusion gene as a model.

P A Pérez-Mancera1, I Sánchez-García.   

Abstract

Chromosomal translocations entail the generation of gene fusions in mesenchymal tumors. Despite the successful identification of these specific and consistent genetic events, the nature of the intimate association between the gene fusion and the resulting phenotype still remains to be elucidated. Here these studies are reviewed, using FUS-DDIT3 as a model to illustrate how they have contributed to current understanding in unique and unexpected ways. FUS-DDIT3 is a chimeric oncogene generated by the most common chromosomal translocation t(12;16)(q13;p11) associated with liposarcomas. The application of transgenic methods to the study of this sarcoma-associated FUS-DDIT3 gene fusion has provided insights into their functions in vivo, and suggested mechanisms by which lineage selection may be achieved.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15826835     DOI: 10.1016/j.semcancer.2005.01.006

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  12 in total

Review 1.  Modeling sarcomagenesis using multipotent mesenchymal stem cells.

Authors:  Rene Rodriguez; Ruth Rubio; Pablo Menendez
Journal:  Cell Res       Date:  2011-09-20       Impact factor: 25.617

2.  Mdm2 controls CREB-dependent transactivation and initiation of adipocyte differentiation.

Authors:  P Hallenborg; S Feddersen; S Francoz; I Murano; U Sundekilde; R K Petersen; V Akimov; M V Olson; G Lozano; S Cinti; B T Gjertsen; L Madsen; J-C Marine; B Blagoev; K Kristiansen
Journal:  Cell Death Differ       Date:  2012-03-02       Impact factor: 15.828

Review 3.  Animal models of soft-tissue sarcoma.

Authors:  Rebecca D Dodd; Jeffery K Mito; David G Kirsch
Journal:  Dis Model Mech       Date:  2010-08-16       Impact factor: 5.758

4.  Mechanical Strain Induces Transcriptomic Reprogramming of Saphenous Vein Progenitors.

Authors:  Davide Maselli; Gloria Garoffolo; Giada Andrea Cassanmagnago; Rosa Vono; Matthijs S Ruiter; Anita C Thomas; Paolo Madeddu; Maurizio Pesce; Gaia Spinetti
Journal:  Front Cardiovasc Med       Date:  2022-05-27

5.  The myxoid/round cell liposarcoma fusion oncogene FUS-DDIT3 and the normal DDIT3 induce a liposarcoma phenotype in transfected human fibrosarcoma cells.

Authors:  Katarina Engström; Helena Willén; Christina Kåbjörn-Gustafsson; Carola Andersson; Marita Olsson; Melker Göransson; Sofia Järnum; Anita Olofsson; Elisabeth Warnhammar; Pierre Aman
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

6.  FUS-DDIT3 prevents the development of adipocytic precursors in liposarcoma by repressing PPARgamma and C/EBPalpha and activating eIF4E.

Authors:  Pedro A Pérez-Mancera; Camino Bermejo-Rodríguez; Manuel Sánchez-Martín; Fernando Abollo-Jiménez; Belén Pintado; Isidro Sánchez-García
Journal:  PLoS One       Date:  2008-07-02       Impact factor: 3.240

Review 7.  Mesenchymal stem cells and their use as cell replacement therapy and disease modelling tool.

Authors:  J García-Castro; C Trigueros; J Madrenas; J A Pérez-Simón; R Rodriguez; P Menendez
Journal:  J Cell Mol Med       Date:  2008-12       Impact factor: 5.310

Review 8.  Advances in the targeted therapy of liposarcoma.

Authors:  Zhonghai Guan; Xiongfei Yu; Haohao Wang; Haiyong Wang; Jing Zhang; Guangliang Li; Jiang Cao; Lisong Teng
Journal:  Onco Targets Ther       Date:  2015-01-05       Impact factor: 4.147

Review 9.  Current classification, treatment options, and new perspectives in the management of adipocytic sarcomas.

Authors:  Alessandro De Vita; Laura Mercatali; Federica Recine; Federica Pieri; Nada Riva; Alberto Bongiovanni; Chiara Liverani; Chiara Spadazzi; Giacomo Miserocchi; Dino Amadori; Toni Ibrahim
Journal:  Onco Targets Ther       Date:  2016-10-11       Impact factor: 4.147

10.  Myxoid liposarcoma-associated EWSR1-DDIT3 selectively represses osteoblastic and chondrocytic transcription in multipotent mesenchymal cells.

Authors:  Kayo Suzuki; Yoshito Matsui; Mami Higashimoto; Yoshiharu Kawaguchi; Shoji Seki; Hiraku Motomura; Takeshi Hori; Yasuhito Yahara; Masahiko Kanamori; Tomoatsu Kimura
Journal:  PLoS One       Date:  2012-05-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.